RPBIF/RBM.TO
drbio, the recent run of RPBIF to $1.00 has made it my second largest holding (behind CAMH). There is definitely huge potential upside, and I would think offers to buy the company might happen at anytime. As I know you know (very well), the ID Biomed guys have a good track record of building and then selling a company. You may be right that RPBIF/RBM has more upside than CAMH.
As for CAMH, I believe it really finds itself in a perfect storm right now. The ICD industry desperately needs something to revive it, and here's a non-invasive test that can work to get more ICD's installed. While STJ has embraced the MTWA test by agreeing to sell the HearTWave units, I expect BSX and MDT to embrace the technology once the installed base of machines is higher. In the end, I don't think STJ struck the deal with CAMH to make lots of money from selling HearTWave machines. I think they struck the deal to accelerate sales of machines because it will sell more ICD's. JMHO, though.
Best regards,
Geoff
News 
Market Data 
Discover 
